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Background: Various antiplatelet and anticoagulant agents are being developed. Co-administration of them will achieve higher anti-thrombotic 
effect, but bleeding events may increase as a trade-off. Although they effect via different mechanisms, potential interactions may exist. We sought to 
explore whether the concurrent clopidogrel usage would affect the peak anti-Xa of enoxaparin and bleeding events frequency.
Methods: Thirty-one patients, whose creatinine clearance were greater than 30 mL/min, presenting with unstable angina (UA) or non-ST 
elevation myocardial infarction (NSTEMI) were enrolled consecutively and prospectively. All patients necessitated at least 3 doses of subcutaneous 
enoxaparin(1 mg/kg q12hr). Three to five doses of enoxaparin were given, then peak anti-Xa was determined at four hours after the last dose. 
Patients were categorized into 2 groups based on concurrent clopidogrel administration or not.
Results: Peak anti-Xa levels were significantly higher in patients receiving concurrent clopidogrel compared to those not receiving clopidogrel 
(n=15,0.87±0.08 vs. n=16,0.72±0.16 IU/mL, P=0.004).More minor bleeding events occurred in patients receiving concurrent clopidogrel.(40% vs. 
6.3%, p=0.037).
Conclusions: Clopidogrel usage is correlated with higher enoxaparin anticoagulation effects in patients of UA/NSTEMI. Minor bleeding tended to 
increase when enoxaparin was used in adjunct with clopidogrel.
Characteristics and anti-Xa levels
Clopidogrel,N=15 Non-clopidogrel,N=16 p
Peak Anti-Xa(IU/mL) 0.87±0.08 0.72±0.16 0.004
Age 63.4±12.1 60.6±8.1 0.457
Female/male 4/11 1/15 0.172
Creatinin clearance (ml/min) 73.6±22.8 77.1±28.1 0.706
Weight(kg) 66.7±14.8 68.5±11.8 0.705
Dose(mg/kg) 0.97±0.05 0.98±0.05 0.360
Number of dosing 4.1±1.0 4.0±0.8 0.843
Aspirin usage 12 16 0.101
Minor bleeding event 6 1 0.037
